<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Edward Marsh PhD on Medium]]></title>
        <description><![CDATA[Stories by Edward Marsh PhD on Medium]]></description>
        <link>https://medium.com/@edmars?source=rss-957de999d2d5------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*pTk_OlpH2fecGjoGD5rcNg.png</url>
            <title>Stories by Edward Marsh PhD on Medium</title>
            <link>https://medium.com/@edmars?source=rss-957de999d2d5------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Fri, 20 Nov 2026 07:10:10 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@edmars/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Anti-aging: Living to 180 — what additional science is needed?]]></title>
            <link>https://medium.com/@edmars/anti-aging-living-to-180-what-additional-science-is-needed-b4e301dce296?source=rss-957de999d2d5------2</link>
            <guid isPermaLink="false">https://medium.com/p/b4e301dce296</guid>
            <category><![CDATA[healthspan]]></category>
            <category><![CDATA[aging]]></category>
            <category><![CDATA[future-technology]]></category>
            <category><![CDATA[longevity]]></category>
            <category><![CDATA[transhumanism]]></category>
            <dc:creator><![CDATA[Edward Marsh PhD]]></dc:creator>
            <pubDate>Mon, 13 Mar 2023 00:19:14 GMT</pubDate>
            <atom:updated>2023-03-22T04:49:23.573Z</atom:updated>
            <content:encoded><![CDATA[<h3>Anti-aging: Living to 180 — what additional science is needed?</h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/640/1*ZC6MVwcsxwTL5iGrSzF2HA.jpeg" /><figcaption>Photo by <a href="https://unsplash.com/@julientromeur?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">julien Tromeur</a> on <a href="https://unsplash.com/photos/V2G1YnMHZwk?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Unsplash</a></figcaption></figure><p>An individual’s age has historically been a useful number because we change in predictable ways throughout our lifespans. Changes up until about twenty to thirty years, we call development. Changes beyond that we call aging. During aging, the changes in our bodies largely make us less and less functional until, finally, a vital organ becomes too dysfunctional and we die. When talking about health and longevity and increasing our longevity, despite time since birth being the traditional predictor, we are really more interested in time until death. A good estimate of this is our functional age — how functional is our body, and how much functional reserve our vital organs have remaining.</p><p>Our functional reserve is depleted by both extrinsic and intrinsic mechanisms. Poor diet, air pollution, emotional stress and physical injuries etc. cause extrinsic depletions on our functional reserves, but can be somewhat alleviated with a healthy lifestyle. However, even with the healthiest lifestyle, our functional reserves intrinsically decline because our cells themselves change over time. Stem cells change to proliferate less (<em>1</em>), neuron cells change to become frail (<em>2</em>), muscle fiber cells contract with less force (<em>3</em>), and epithelial cells protect our skin less (<em>4</em>), as a few examples. With modern biological advances however, there is hope for reducing or reversing how our cells change over time, increasing the functional reserve of our organs and an individual’s time until death.</p><p>The behaviors of our cells are fundamentally governed by instructions encoded in our DNA. In the last decade we have learned the DNA sequences, called genes, to explicitly reprogram our cells to regain and indefinitely maintain particular functional states (<em>5,6</em>). These were discovered by identifying the genes that turn on in the embryo in order to reset the intrinsic age of the parental egg and sperm. Combined with building a new body, the baby is thus both extrinsically and intrinsically reset in age. The discovery of these genes by Shinya Yamanaka won him the Nobel Prize in 2012. Reprogramming the intrinsic age of cells in this way has increased the proliferative capabilities of cells in culture (<em>7</em>), increased the functional reserve of organs (8,9) and increased the lifespans of adult mice (<em>10,11,12</em>).</p><p>The functional reserve of our organs and bodies can be measured macroscopically in a variety of minimally invasive ways including VO2max (<em>13</em>), cancer (<em>14</em>), muscle mass (<em>15</em>), and others (<em>16</em>). Programs to comprehensively quantify and share biomarkers are further helping to understand what is normal and how amenable to improvement these aging markers are in real, healthy, humans (<em>17,18</em>). In recent years, highly quantitative biomarkers have also been identified to measure the functional reserve of our individual cells (<em>19,20,21</em>). These cellular markers are naturally occurring chemical modifications on a cell’s DNA, known as epigenetic modifications, that a cell uses to organize its DNA. Statistical models looking at hundreds of epigenetic modifications in aggregate can be used to understand the functional reserve of cells and organs. While highly quantitative and accurate, this approach requires a sample of cells and thus may be highly invasive. However, for easily accessible cells, such as those in saliva, blood, and urine, companies exist that will receive samples from you and tell you your functional age based on these clocks (<em>22,23,24</em>). Taken all together, a person’s functional reserve can be well quantified.</p><p>With this knowledge of which genes to use to reprogram cells back to a higher functional reserve and of how to measure the effects of that reprogramming, the remaining hurdle is the safe delivery of these genes into the trillions (<em>25</em>) of individual cells that make up the adult human.</p><p>Gene therapy is the field that focuses on delivering DNA into existing cells in the adult. It has been the subject of intense interest and research for several decades and has shown great promise in recent clinical applications (<em>26</em>). Once injected into the body a DNA molecule must enter a cell to have any effect. However, DNA does not naturally enter cells, and, free floating, it is rapidly degraded. There are several mechanisms to deliver DNA into cells, but viruses are an effective vehicle that have evolved to efficiently transmit their DNA into human cells. While many viruses are dangerous pathogens, other viruses are largely non-symptomatic in humans and are used in modern gene therapies.</p><p>One such benign virus is called Adeno Associated Virus (AAV). AAVs are composed of two parts, both of which can be altered for therapeutic purposes: 1) the DNA inside the AAV that will be delivered to the target cells. In the lab, AAVs can be made to carry any DNA (limited by what will fit). 2) an outer protein shell, called a capsid, that protects its DNA and has an affinity for entering into certain target cells. In the last two years, capsids with strong affinities for muscle, brain, and mouse T cells have been demonstrated (<em>27,28,29</em>).</p><p>It is currently not possible to make an AAV that targets all cell types equally, as the affinity of the capsid to a cell depends on the proteins on the surface of that cell and different cells have different proteins. As a result, we need to build multiple different capsids that target multiple different cell types to cover as much of the body as possible. Important cell types that are generically present across all our organs include fibroblasts, tissue resident macrophages, adipocytes, epithelial and endothelial cells. Additionally, specific cell types of vital organs that should also be targeted include skeletal muscle fibers, cardiac myocytes, hematopoietic stem cells, neurons, smooth muscle and bone cells (osteocytes).</p><p>Beyond cell specific targeting, three other “to-do” items exist for AAV gene therapy. 1) reducing the high cost of production of the large quantities of pure virus needed, 2) reducing the production of neutralizing antibodies against AAV that make multiple treatments difficult, and 3) characterizing the immune response to the DNA sequences delivered. Solutions to all three exist, but more work is needed.</p><p>We are tantalizingly close to increasing the lifespan of humans, but more work is needed in gene therapy science to cross the finish line. That scientific work needs funding, whether from public or private entities interested in longevity (<em>30,31,32</em>). Aging research benefits everyone as an understanding of aging and how cells change with time is fundamental to the study of biology and disease.</p><p><strong><em>References</em></strong></p><p>1. Brunet, A., Goodell, M. A. &amp; Rando, T. A. Ageing and rejuvenation of tissue stem cells and their niches. <em>Nat. Rev. Mol. Cell Biol.</em> <strong>24</strong>, 45–62 (2023). <a href="https://pubmed.ncbi.nlm.nih.gov/35859206/">https://pubmed.ncbi.nlm.nih.gov/35859206/</a></p><p>2. Castelli, V. <em>et al.</em> Neuronal Cells Rearrangement During Aging and Neurodegenerative Disease: Metabolism, Oxidative Stress and Organelles Dynamic. <em>Front. Mol. Neurosci.</em> <strong>12</strong>, 132 (2019). <a href="https://pubmed.ncbi.nlm.nih.gov/31191244/">https://pubmed.ncbi.nlm.nih.gov/31191244/</a></p><p>3. Miljkovic, N., Lim, J.-Y., Miljkovic, I. &amp; Frontera, W. R. Aging of skeletal muscle fibers. <em>Ann. Rehabil. Med.</em> <strong>39</strong>, 155–62 (2015). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414960/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414960/</a></p><p>4. Parrish, A. R. The impact of aging on epithelial barriers. <em>Tissue barriers</em> <strong>5</strong>, e1343172 (2017). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788442">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788442</a></p><p>5. Takahashi, K. &amp; Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. <em>Cell</em> <strong>126</strong>, 663–76 (2006). <a href="https://pubmed.ncbi.nlm.nih.gov/16904174/">https://pubmed.ncbi.nlm.nih.gov/16904174/</a></p><p>6. Nakagawa, M. &amp; Yamanaka, S. Reprogramming of somatic cells to pluripotency. <em>Adv. Exp. Med. Biol.</em> <strong>695</strong>, 215–24 (2010). <a href="https://pubmed.ncbi.nlm.nih.gov/21222208/">https://pubmed.ncbi.nlm.nih.gov/21222208/</a></p><p>7. Kisby, T., de Lázaro, I., Stylianou, M., Cossu, G. &amp; Kostarelos, K. Transient reprogramming of postnatal cardiomyocytes to a dedifferentiated state. <em>PLoS One</em> <strong>16</strong>, e0251054 (2021). <a href="https://pubmed.ncbi.nlm.nih.gov/33951105/">https://pubmed.ncbi.nlm.nih.gov/33951105/</a></p><p>8. Wendorff, A. A. <em>et al.</em> Epigenetic reversal of hematopoietic stem cell aging in Phf6-knockout mice. <em>Nat. Aging</em> <strong>2</strong>, 1008–1023 (2022). <a href="https://www.nature.com/articles/s43587-022-00304-x">https://www.nature.com/articles/s43587-022-00304-x</a></p><p>9. Lu, Y. <em>et al.</em> Reprogramming to recover youthful epigenetic information and restore vision. <em>Nature</em> <strong>588</strong>, 124–129 (2020). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752134/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752134/</a></p><p>10. Macip and Davidsohn et al. Rejuvenate Bio. 2023. “Gene Therapy Mediated Partial Reprogramming Extends Lifespan and Reverses Age-Related Changes in Aged Mice”. <a href="https://www.biorxiv.org/content/10.1101/2023.01.04.522507v1">https://www.biorxiv.org/content/10.1101/2023.01.04.522507v1</a></p><p>11. Jaijyan, D. K. <em>et al.</em> New intranasal and injectable gene therapy for healthy life extension. <em>Proc. Natl. Acad. Sci. U. S. A.</em> <strong>119</strong>, e2121499119 (2022). <a href="https://pubmed.ncbi.nlm.nih.gov/35537048/">https://pubmed.ncbi.nlm.nih.gov/35537048/</a></p><p>12. Ocampo, A. <em>et al.</em> In Vivo Amelioration of Age-Associated Hallmarks by Partial Reprogramming. <em>Cell</em> <strong>167</strong>, 1719–1733.e12 (2016). <a href="https://pubmed.ncbi.nlm.nih.gov/27984723/">https://pubmed.ncbi.nlm.nih.gov/27984723/</a></p><p>13. Strasser, B. &amp; Burtscher, M. Survival of the fittest: VO2max, a key predictor of longevity? <em>Front. Biosci. (Landmark Ed.</em> <strong>23</strong>, 1505–1516 (2018). <a href="https://pubmed.ncbi.nlm.nih.gov/29293447/">https://pubmed.ncbi.nlm.nih.gov/29293447/</a></p><p>14. <a href="https://www.galleri.com/">https://www.galleri.com/</a></p><p>15. Farrow, M. <em>et al.</em> The effect of ageing on skeletal muscle as assessed by quantitative MR imaging: an association with frailty and muscle strength. <em>Aging Clin. Exp. Res.</em> <strong>33</strong>, 291–301 (2021). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914187/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914187/</a></p><p>16. Wagner, K.-H., Cameron-Smith, D., Wessner, B. &amp; Franzke, B. Biomarkers of Aging: From Function to Molecular Biology. <em>Nutrients</em> <strong>8</strong>, (2016). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924179/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924179/</a></p><p>17. <a href="https://blueprint.bryanjohnson.co/#routine-measurement">https://blueprint.bryanjohnson.co/#routine-measurement</a></p><p>18. <a href="https://rejuvenationolympics.com/leaderboard/">https://rejuvenationolympics.com/leaderboard/</a></p><p>19. Horvath, S. DNA methylation age of human tissues and cell types. <em>Genome Biol.</em> <strong>14</strong>, R115 (2013). <a href="https://pubmed.ncbi.nlm.nih.gov/24138928/">https://pubmed.ncbi.nlm.nih.gov/24138928/</a></p><p>20. Levine, M. E. <em>et al.</em> An epigenetic biomarker of aging for lifespan and healthspan. <em>Aging (Albany. NY).</em> <strong>10</strong>, 573–591 (2018). <a href="https://pubmed.ncbi.nlm.nih.gov/29676998/">https://pubmed.ncbi.nlm.nih.gov/29676998/</a></p><p>21. Ryan, C. P. ‘Epigenetic clocks’: Theory and applications in human biology. <em>Am. J. Hum. Biol.</em> <strong>33</strong>, e23488 (2021). <a href="https://pubmed.ncbi.nlm.nih.gov/32845048/">https://pubmed.ncbi.nlm.nih.gov/32845048/</a></p><p>22. <a href="https://www.mydnage.com/">https://www.mydnage.com/</a></p><p>23. <a href="https://www.elysiumhealth.com/">https://www.elysiumhealth.com/</a></p><p>24. <a href="https://trudiagnostic.com/products/truage-complete-epigenetic-collection">https://trudiagnostic.com/products/truage-complete-epigenetic-collection</a></p><p>25. Bianconi, E. <em>et al.</em> An estimation of the number of cells in the human body. <em>Ann. Hum. Biol.</em> <strong>40</strong>, 463–71 (2013). <a href="https://pubmed.ncbi.nlm.nih.gov/23829164/">https://pubmed.ncbi.nlm.nih.gov/23829164/</a></p><p>26. Bulaklak, K. &amp; Gersbach, C. A. The once and future gene therapy. <em>Nat. Commun.</em> <strong>11</strong>, 5820 (2020). <a href="https://pubmed.ncbi.nlm.nih.gov/33199717/">https://pubmed.ncbi.nlm.nih.gov/33199717/</a></p><p>27. Tabebordbar, M. <em>et al.</em> Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species. <em>Cell</em> <strong>184</strong>, 4919–4938.e22 (2021). <a href="https://pubmed.ncbi.nlm.nih.gov/34506722/">https://pubmed.ncbi.nlm.nih.gov/34506722/</a></p><p>28. Goertsen, D. <em>et al.</em> AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset. <em>Nat. Neurosci.</em> <strong>25</strong>, 106–115 (2022). <a href="https://pubmed.ncbi.nlm.nih.gov/34887588/">https://pubmed.ncbi.nlm.nih.gov/34887588/</a></p><p>29. Nyberg, W. A. <em>et al.</em> An evolved AAV variant enables efficient genetic engineering of murine T cells. <em>Cell</em> <strong>186</strong>, 446–460.e19 (2023). <a href="https://pubmed.ncbi.nlm.nih.gov/36638795/">https://pubmed.ncbi.nlm.nih.gov/36638795/</a></p><p>30. <a href="https://www.calicolabs.com/">https://www.calicolabs.com/</a></p><p>31. <a href="https://altoslabs.com/">https://altoslabs.com/</a></p><p>32. <a href="https://blueprint.bryanjohnson.co/">https://blueprint.bryanjohnson.co/</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=b4e301dce296" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>